Kole Roybal, PhD

Title(s)Professor, Microbiology and Immunology
SchoolSchool of Medicine
Address513 Parnassus Avenue, HSE, #301H
San Francisco CA 94143
Phone415-476-8289
PronounsHe/Him/His
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    UT Southwestern Medical Center Ph.D.2013Immunology
    Austin CollegeB.A.2005Biology
    Collapse awards and honors
    NIH - National Cancer Institute2018  - 2023NIH New Innovator Award
    Science Magazine & Sartorius2018Award for Regenerative Medicine and Cell Therapy
    Parker Institute for Cancer Immunotherapy2017Member Researcher
    Chan Zuckerberg Biohub2017Chan Zuckerberg Biohub Investigator
    Jane Coffin Childs Memorial Fund2014  - 2017Postdoctoral Fellowship
    National Institutes of Health2007  - 2010Ruth L. Kirschstein National Research Service Award

    Collapse Overview 
    Collapse overview
    In the Roybal Lab we harness the tools of synthetic and chemical biology to enhance the therapeutic potential of engineered immune cells. We take a comprehensive approach to cellular engineering by developing new synthetic receptors, signal transduction cascades, and cellular response programs to enhance the safety and effectiveness of adoptive cell therapies. We also study the logic of natural cellular signaling systems, and the underlying principles of cellular communication and collective cell behavior during an immune response.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Abstract A026: Deciphering natural and synthetic genetic programs governing human T cell function with combinatorial CRISPR activation and interference screens. Cancer Immunology Research. 2025 Feb 23; 13(2_Supplement):a026-a026. Steinhart SZ, Perera PJ, Dorovskyi DD, Workley WL, Tran TC, Hernandez HR, Li LZ, Foisey FM, Goodman GD, Roybal RK, Shy SB, Marson MA. .
      View in: Publisher Site   Mentions:
    2. Engineered receptors for soluble cellular communication and disease sensing. Nature. 2025 Feb; 638(8051):805-813. Piraner DI, Abedi MH, Duran Gonzalez MJ, Chazin-Gray A, Lin A, Zhu I, Ravindran PT, Schlichthaerle T, Huang B, Bearchild TH, Lee D, Wyman S, Jun YW, Baker D, Roybal KT. PMID: 39542025; PMCID: PMC11839477.
      View in: PubMed   Mentions: 1     Fields:    
    3. Designed endocytosis-inducing proteins degrade targets and amplify signals. Nature. 2025 Feb; 638(8051):796-804. Huang B, Abedi M, Ahn G, Coventry B, Sappington I, Tang C, Wang R, Schlichthaerle T, Zhang JZ, Wang Y, Goreshnik I, Chiu CW, Chazin-Gray A, Chan S, Gerben S, Murray A, Wang S, O'Neill J, Yi L, Yeh R, Misquith A, Wolf A, Tomasovic LM, Piraner DI, Duran Gonzalez MJ, Bennett NR, Venkatesh P, Ahlrichs M, Dobbins C, Yang W, Wang X, Sahtoe DD, Vafeados D, Mout R, Shivaei S, Cao L, Carter L, Stewart L, Spangler JB, Roybal KT, Greisen PJ, Li X, Bernardes GJL, Bertozzi CR, Baker D. PMID: 39322662; PMCID: PMC11839401.
      View in: PubMed   Mentions: 6     Fields:    
    4. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2024 07 09; 8(13):3562-3575. Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, Chang H, Bridge M, Kwek S, Cheung A, Bylsma S, Hansen E, Wolf J, Wong S, Shah N, Roybal KT, Martin T, Ye CJ, Fong L. PMID: 38574299; PMCID: PMC11319832.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    5. Naturally occurring T cell mutations enhance engineered T cell therapies. Nature. 2024 Feb; 626(7999):626-634. Garcia J, Daniels J, Lee Y, Zhu I, Cheng K, Liu Q, Goodman D, Burnett C, Law C, Thienpont C, Alavi J, Azimi C, Montgomery G, Roybal KT, Choi J. PMID: 38326614; PMCID: PMC11573425.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    6. Naturally Occurring Mutations in Human T Cell Lymphomas Enhance Engineered T Cell Therapies. Blood. 2023 Nov 28; 142(Supplement 1):884. Garcia GJ, Daniels DJ, Lee LY, Zhu ZI, Cheng CK, Liu LQ, Goodman GD, Burnett BC, Law LC, Thienpoint TC, Alavi AJ, Azimi AC, Montgomery MG, Roybal RK, Choi CJ. .
      View in: Publisher Site   Mentions:
    7. Designed Endocytosis-Triggering Proteins mediate Targeted Degradation. bioRxiv. 2023 Sep 20. Huang B, Abedi M, Ahn G, Coventry B, Sappington I, Wang R, Schlichthaerle T, Zhang JZ, Wang Y, Goreshnik I, Chiu CW, Chazin-Gray A, Chan S, Gerben S, Murray A, Wang S, O'Neill J, Yeh R, Misquith A, Wolf A, Tomasovic LM, Piraner DI, Gonzalez MJD, Bennett NR, Venkatesh P, Satoe D, Ahlrichs M, Dobbins C, Yang W, Wang X, Vafeados D, Mout R, Shivaei S, Cao L, Carter L, Stewart L, Spangler JB, Bernardes GJL, Roybal KT, Greisen P, Li X, Bertozzi C, Baker D. PMID: 37781607; PMCID: PMC10541094.
      View in: PubMed   Mentions:
    8. Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies. Cancer Immunol Res. 2023 08 03; 11(8):1030-1043. Zhu I, Piraner DI, Roybal KT. PMID: 37429007; PMCID: PMC10527511.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    9. Toward the clinical development of synthetic immunity to cancer. Immunol Rev. 2023 11; 320(1):83-99. Garcia JM, Burnett CE, Roybal KT. PMID: 37491719.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science. 2022 12 16; 378(6625):eaba1624. Allen GM, Frankel NW, Reddy NR, Bhargava HK, Yoshida MA, Stark SR, Purl M, Lee J, Yee JL, Yu W, Li AW, Garcia KC, El-Samad H, Roybal KT, Spitzer MH, Lim WA. PMID: 36520915; PMCID: PMC9970000.
      View in: PubMed   Mentions: 76     Fields:    
    11. Multidimensional control of therapeutic human cell function with synthetic gene circuits. Science. 2022 12 16; 378(6625):1227-1234. Li HS, Israni DV, Gagnon KA, Gan KA, Raymond MH, Sander JD, Roybal KT, Joung JK, Wong WW, Khalil AS. PMID: 36520914; PMCID: PMC10054295.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    12. Hyperstabilization of T cell microvilli contacts by chimeric antigen receptors. J Cell Biol. 2023 03 06; 222(3). Beppler C, Eichorst J, Marchuk K, Cai E, Castellanos CA, Sriram V, Roybal KT, Krummel MF. PMID: 36520493; PMCID: PMC9757849.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    13. Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies. Sci Transl Med. 2022 11 09; 14(670):eabm1463. Goodman DB, Azimi CS, Kearns K, Talbot A, Garakani K, Garcia J, Patel N, Hwang B, Lee D, Park E, Vykunta VS, Shy BR, Ye CJ, Eyquem J, Marson A, Bluestone JA, Roybal KT. PMID: 36350984; PMCID: PMC9939256.
      View in: PubMed   Mentions: 26     Fields:    
    14. Diminished cell proliferation promotes natural killer cell adaptive-like phenotype by limiting FcεRIγ expression. J Exp Med. 2022 11 07; 219(11). Shemesh A, Su Y, Calabrese DR, Chen D, Arakawa-Hoyt J, Roybal KT, Heath JR, Greenland JR, Lanier LL. PMID: 36066491; PMCID: PMC9448639.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    15. Antigen-Dependent Inducible T-Cell Reporter System for PET Imaging of Breast Cancer and Glioblastoma. J Nucl Med. 2023 01; 64(1):137-144. Shin J, Parker MFL, Zhu I, Alanizi A, Rodriguez CI, Liu R, Watchmaker PB, Kalita M, Blecha J, Luu J, Wright B, Lapi SE, Flavell RR, Okada H, Tlsty TD, Roybal KT, Wilson DM. PMID: 35981900; PMCID: PMC9841254.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    16. Differential IL-12 signaling induces human natural killer cell activating receptor-mediated ligand-specific expansion. J Exp Med. 2022 08 01; 219(8). Shemesh A, Pickering H, Roybal KT, Lanier LL. PMID: 35758909; PMCID: PMC9240274.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    17. Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell. 2022 04 14; 185(8):1431-1443.e16. Zhu I, Liu R, Garcia JM, Hyrenius-Wittsten A, Piraner DI, Alavi J, Israni DV, Liu B, Khalil AS, Roybal KT. PMID: 35427499; PMCID: PMC9108009.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    18. Cellular Structures Controlling T Cell Signaling in Time and Space. . 2022 Jan 1; (Annu Rev Immunol 36 2018). Roybal RK, Alamir AH, Lu LJ, Wülfing WC. .
      View in: Publisher Site   Mentions:
    19. Synthetic biology: at the crossroads of genetic engineering and human therapeutics-a Keystone Symposia report. Ann N Y Acad Sci. 2021 12; 1506(1):98-117. Cable J, Leonard JN, Lu TK, Xie Z, Chang MW, Fernández LÁ, Lora JM, Kaufman HL, Quintana FJ, Geiger R, F Lesser C, Lynch JP, Hava DL, Cornish VW, Lee GK, DiAndreth B, Fero M, Srivastava R, De Coster T, Roybal KT, Rackham OJL, Kiani S, Zhu I, Hernandez-Lopez RA, Guo T, Chen WCW. PMID: 34786712.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    20. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021 04 28; 13(591). Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, Cho J, Briones JD, Duecker JM, Goretsky YE, Dannenfelser R, Cardarelli L, Troyanskaya O, Sidhu SS, Roybal KT, Okada H, Lim WA. PMID: 33910979; PMCID: PMC8362330.
      View in: PubMed   Mentions: 201     Fields:    Translation:AnimalsCells
    21. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. 2021 04 28; 13(591). Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N, Montgomery G, Liu B, Roybal KT. PMID: 33910981; PMCID: PMC8594452.
      View in: PubMed   Mentions: 99     Fields:    
    22. DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation. Nat Nanotechnol. 2021 02; 16(2):214-223. Huang X, Williams JZ, Chang R, Li Z, Burnett CE, Hernandez-Lopez R, Setiady I, Gai E, Patterson DM, Yu W, Roybal KT, Lim WA, Desai TA. PMID: 33318641; PMCID: PMC7878327.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    23. Precise T cell recognition programs designed by transcriptionally linking multiple receptors. Science. 2020 11 27; 370(6520):1099-1104. Williams JZ, Allen GM, Shah D, Sterin IS, Kim KH, Garcia VP, Shavey GE, Yu W, Puig-Saus C, Tsoi J, Ribas A, Roybal KT, Lim WA. PMID: 33243890; PMCID: PMC8054651.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimalsCells
    24. IMMU-33. MULTI-ANTIGEN RECOGNITION CIRCUITS OVERCOME CHALLENGES OF SPECIFICITY, HETEROGENEITY, AND DURABILITY IN T-CELL THERAPY FOR GLIOBLASTOMA. Neuro-Oncology. 2020 Nov 9; 22(Supplement_2):ii111-ii112. Watchmaker WP, Choe CJ, Simic SM, Gilbert GR, li lA, Krasnow KN, Carrera CD, Yu YW, Downey DK, Celli CA, Cho CJ, Briones BJ, Dannenfelser DR, Cardarelli CL, Sidhu SS, Roybal RK, Lim LW, Okada OH. .
      View in: Publisher Site   Mentions:
    25. MM-378: Inhibitory and Stimulatory Interplay Between Myeloma Tumor and T Cells. Clinical Lymphoma Myeloma & Leukemia. 2020 Sep 1; 20:s309. Dietrich DA, Burnett BC, Martin MT, Wiita WA, Roybal RK, Eyquem EJ. .
      View in: Publisher Site   Mentions:
    26. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv. 2020 07 14; 4(13):2899-2911. Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. PMID: 32589729; PMCID: PMC7362346.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    27. convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting. Commun Biol. 2020 06 09; 3(1):296. Landgraf KE, Williams SR, Steiger D, Gebhart D, Lok S, Martin DW, Roybal KT, Kim KC. PMID: 32518350; PMCID: PMC7283332.
      View in: PubMed   Mentions: 24  Translation:HumansAnimalsCells
    28. Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies. Cell. 2020 Apr 30; 181(3):728-744.e21. Roth TL, Li PJ, Blaeschke F, Nies JF, Apathy R, Mowery C, Yu R, Nguyen MLT, Lee Y, Truong A, Hiatt J, Wu D, Nguyen DN, Goodman D, Bluestone JA, Ye CJ, Roybal K, Shifrut E, Marson A. PMID: 32302591; PMCID: PMC7219528.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansAnimalsCells
    29. IMMU-21. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION. Neuro-Oncology. 2019 Nov 11; 21(Supplement_6):vi123-vi123. Watchmaker WP, Choe CJ, Carrera CD, Gilbert GR, Yu YW, Downey DK, Roybal RK, Lim LW, Okada OH. .
      View in: Publisher Site   Mentions:
    30. Paving New Roads for CARs. Trends Cancer. 2019 10; 5(10):583-592. Hyrenius-Wittsten A, Roybal KT. PMID: 31706506.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    31. NextGen cell-based immunotherapies in cancer and other immune disorders. Curr Opin Immunol. 2019 08; 59:79-87. Azimi CS, Tang Q, Roybal KT, Bluestone JA. PMID: 31071513.
      View in: PubMed   Mentions: 4     Fields:    
    32. Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity. 2019 02 19; 50(2):477-492.e8. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. PMID: 30737146; PMCID: PMC6886475.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansAnimalsCells
    33. Abstract B044: Engineering CAR NK cells for antigen-dependent autocrine expansion. Convergence of Technology and Cancer Immunotherapy. 2019 Feb 1; b044-b044. Shemesh SA, Roybal RK, Lanier LL. .
      View in: Publisher Site   Mentions:
    34. Beyond the TCR, Antigen Discrimination in T Cells Continues in the LAT:GRB2:SOS Protein Condensate. Biophysical Journal. 2019 Feb 1; 116(3):530a. Low-Nam LS, Lin LJ, McAffee MD, Alvarez AS, Hansen HS, Roybal RK, Groves GJ. .
      View in: Publisher Site   Mentions:
    35. Identifying Factors in Multiple Myeloma Controlling Response to B-Cell Maturation Antigen (BCMA)-Targeted Immunotherapy Using CRISPR-Based Functional Genomics. Blood. 2018 Nov 29; 132(Supplement 1):1926-1926. Ramkumar RP, Leong LJ, Seyler SM, Georgoulis GS, Hyrenius Wittsten HA, Choudhry CP, Roybal RK, Wiita WA, Kampmann KM. .
      View in: Publisher Site   Mentions:
    36. IMMU-57. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION. Neuro-Oncology. 2018 Nov 5; 20(suppl_6):vi134-vi134. Watchmaker WP, Choe CJ, Carrera CD, Downey DK, Shahin SM, Roybal RK, Lim LW, Okada OH. .
      View in: Publisher Site   Mentions:
    37. Abstract 2981: Clonal deletion of tumor-specific T cells by combination checkpoint blockade compromises antitumor efficacy in low tumor burden states. Immunology. 2018 Jul 1; 2981-2981. Pai PC, Lu LX, Simons SD, DuPage DM, Roybal RK, Chen CM, Kwek KS, Casbon CA, Kinsbury KG, Fong FL. .
      View in: Publisher Site   Mentions:
    38. Refining cell therapy. Science. 2018 Mar 09; 359(6380):1112-1113. Roybal KT. PMID: 29590036.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    39. Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities. Annu Rev Immunol. 2017 04 26; 35:229-253. Roybal KT, Lim WA. PMID: 28446063; PMCID: PMC5555230.
      View in: PubMed   Mentions: 58     Fields:    
    40. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017 04 07; 7(1):737. Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, Marson A. PMID: 28389661; PMCID: PMC5428439.
      View in: PubMed   Mentions: 339     Fields:    Translation:HumansAnimalsCells
    41. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell. 2016 Oct 06; 167(2):419-432.e16. Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, Walker WJ, McNally KA, Lim WA. PMID: 27693353; PMCID: PMC5072533.
      View in: PubMed   Mentions: 300     Fields:    
    42. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. The Journal of Immunology. 2016 May 1; 196(1_Supplement):214.24-214.24. Rupp RL, Schumann SK, Roybal RK, Marson MA, Lim LW. .
      View in: Publisher Site   Mentions:
    43. Computational spatiotemporal analysis identifies WAVE2 and cofilin as joint regulators of costimulation-mediated T cell actin dynamics. Sci Signal. 2016 Apr 19; 9(424):rs3. Roybal KT, Buck TE, Ruan X, Cho BH, Clark DJ, Ambler R, Tunbridge HM, Zhang J, Verkade P, Wülfing C, Murphy RF. PMID: 27095595; PMCID: PMC4871116.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    44. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell. 2016 Feb 11; 164(4):780-91. Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, Lim WA. PMID: 26830878; PMCID: PMC4752866.
      View in: PubMed   Mentions: 416     Fields:    
    45. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Cell. 2016 Feb 11; 164(4):770-9. Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, Lim WA. PMID: 26830879; PMCID: PMC4752902.
      View in: PubMed   Mentions: 456     Fields:    
    46. Cellular Structures Controlling T Cell Signaling in Time and Space. Encyclopedia of Cell Biology. 2016 Jan 1; 677-686. Wülfing WC, Roybal RK. .
      View in: Publisher Site   Mentions:
    47. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015 Oct 16; 350(6258):aab4077. Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. PMID: 26405231; PMCID: PMC4721629.
      View in: PubMed   Mentions: 324     Fields:    
    48. Modest Interference with Actin Dynamics in Primary T Cell Activation by Antigen Presenting Cells Preferentially Affects Lamellal Signaling. PLoS One. 2015; 10(8):e0133231. Roybal KT, Mace EM, Clark DJ, Leard AD, Herman A, Verkade P, Orange JS, Wülfing C. PMID: 26237588; PMCID: PMC4523178.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    49. Early Signaling in Primary T Cells Activated by Antigen Presenting Cells Is Associated with a Deep and Transient Lamellal Actin Network. PLoS One. 2015; 10(8):e0133299. Roybal KT, Mace EM, Mantell JM, Verkade P, Orange JS, Wülfing C. PMID: 26237050; PMCID: PMC4523204.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    50. Synthetic biology approaches to engineer T cells. Curr Opin Immunol. 2015 Aug; 35:123-30. Wu CY, Rupp LJ, Roybal KT, Lim WA. PMID: 26218616; PMCID: PMC4553068.
      View in: PubMed   Mentions: 11     Fields:    
    51. Cellular structures controlling T cell signaling in time and space. Encyclopedia of Cell Biology. 2015; 677-686. Wülfing C, Roybal KT. View Publication.
    52. IFN-α suppresses GATA3 transcription from a distal exon and promotes H3K27 trimethylation of the CNS-1 enhancer in human Th2 cells. J Immunol. 2014 Jun 15; 192(12):5687-94. Huber JP, Gonzales-van Horn SR, Roybal KT, Gill MA, Farrar JD. PMID: 24813204; PMCID: PMC4104489.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    53. Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors. MAbs. 2014 Jan-Feb; 6(1):108-18. Furlan SN, Mandraju R, Brewer T, Roybal K, Troutman TD, Hu W, Palm NW, Unni A, Pasare C. PMID: 24284965; PMCID: PMC3929435.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    54. The actin-driven spatiotemporal organization of T-cell signaling at the system scale. Immunol Rev. 2013 Nov; 256(1):133-47. Roybal KT, Sinai P, Verkade P, Murphy RF, Wülfing C. PMID: 24117818.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    55. Differential regulation of the period genes in striatal regions following cocaine exposure. PLoS One. 2013; 8(6):e66438. Falcon E, Ozburn A, Mukherjee S, Roybal K, McClung CA. PMID: 23776671; PMCID: PMC3679086.
      View in: PubMed   Mentions: 27     Fields:    Translation:Animals
    56. New TACTICS for finding Numb. Immunol Cell Biol. 2013 Jan; 91(1):1-2. Roybal KT, Wülfing C. PMID: 23183270.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    57. Mycobacterial shuttle vectors designed for high-level protein expression in infected macrophages. Appl Environ Microbiol. 2012 Oct; 78(19):6829-37. Eitson JL, Medeiros JJ, Hoover AR, Srivastava S, Roybal KT, Aínsa JA, Hansen EJ, Gumbo T, van Oers NS. PMID: 22820329; PMCID: PMC3457510.
      View in: PubMed   Mentions: 6     Fields:    Translation:Cells
    58. The CD3 zeta subunit contains a phosphoinositide-binding motif that is required for the stable accumulation of TCR-CD3 complex at the immunological synapse. J Immunol. 2011 Jun 15; 186(12):6839-47. DeFord-Watts LM, Dougall DS, Belkaya S, Johnson BA, Eitson JL, Roybal KT, Barylko B, Albanesi JP, Wülfing C, van Oers NS. PMID: 21543646; PMCID: PMC3110614.
      View in: PubMed   Mentions: 36     Fields:    
    59. Tentative and transient natural killer cell polarization balances the requirements for discriminatory recognition and cytolytic efficacy. Commun Integr Biol. 2010 Nov; 3(6):545-8. Sinai P, Roybal KT, Wülfing C. PMID: 21331235; PMCID: PMC3038059.
      View in: PubMed   Mentions: 2  
    60. Inhibiting the inhibitor of the inhibitor: blocking PKC-theta to enhance regulatory T cell function. Sci Signal. 2010 Jul 27; 3(132):pe24. Roybal KT, Wülfing C. PMID: 20664063.
      View in: PubMed   Mentions: 4     Fields:    
    61. Spatiotemporal patterning during T cell activation is highly diverse. Sci Signal. 2009 Apr 07; 2(65):ra15. Singleton KL, Roybal KT, Sun Y, Fu G, Gascoigne NR, van Oers NS, Wülfing C. PMID: 19351954; PMCID: PMC2694444.
      View in: PubMed   Mentions: 39     Fields:    
    62. Spatiotemporal patterning of T cell signaling as an important regulator of T cell activation at the systems level. The FASEB Journal. 2008 Mar 1; 22:1064.16-1064.16. Wuelfing WC, Singleton SK, Roybal RK, Sun SY. .
      View in: Publisher Site   Mentions:
    63. Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A. 2007 Apr 10; 104(15):6406-11. Roybal K, Theobold D, Graham A, DiNieri JA, Russo SJ, Krishnan V, Chakravarty S, Peevey J, Oehrlein N, Birnbaum S, Vitaterna MH, Orsulak P, Takahashi JS, Nestler EJ, Carlezon WA, McClung CA. PMID: 17379666; PMCID: PMC1851061.
      View in: PubMed   Mentions: 302     Fields:    
    Kole's Networks
    Concepts (218)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (45)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.